Gastric cardia adenocarcinoma

Summary

Gastric cardia adenocarcinoma (MONDO:0003835) is a disease and 4 clinical trials. Top therapeutic interventions include leucovorin and adavosertib. A subtype of gastric cardia carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric cardia adenocarcinoma
Mondo ID	MONDO:0003835
DOID	DOID:6271
ICD-11	323129890
NCIT	C5247
UMLS	C1333762
MedGen	232543
GARD	0027650
Anatomy (UBERON)	UBERON:0001162
Is cancer (heuristic)	no

Also known as: adenocarcinoma of cardia of stomach · adenocarcinoma of the cardia of the stomach · adenocarcinoma of the gastric cardia · cardia of stomach adenocarcinoma

Disease family

This is a subtype of gastric cardia carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastric cancer › cardia cancer › gastric cardia carcinoma › gastric cardia adenocarcinoma

Related subtypes (1): carcinoma in situ of gastric cardia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02037048	PHASE2	UNKNOWN	FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
NCT02730546	PHASE1/PHASE2	COMPLETED	Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
NCT04460937	PHASE1	ACTIVE_NOT_RECRUITING	Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
NCT01635595	Not specified	COMPLETED	Nodal Status in Adenocarcinoma of the Esophagus an Cardia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEUCOVORIN	4	2
ADAVOSERTIB	2	1